Covid-19 in cystic fibrosis patients compared to the general population : Severity and virus-host cell interactions
Copyright © 2024. Published by Elsevier B.V..
BACKGROUND: People with cystic fibrosis (pwCF) are considered at risk of developing severe forms of respiratory viral infections. We studied the consequences of COVID-19 and virus-host cell interactions in CF vs. non-CF individuals.
METHODS: We enrolled CF and non-CF individuals, with /without COVID-like symptoms, who underwent nasopharyngeal swab for detection of SARS-CoV-2. Gene expression was evaluated by RNA sequencing on the same nasopharyngeal swabs. Criteria for COVID-19 severity were hospitalization and requirement or increased need of oxygen therapy.
RESULTS: The study included 171 patients (65 pwCF and 106 non-CF individuals). Among them, 10 pwCF (15.4 %) and 43 people without CF (40.6 %) tested positive at RT-PCR. Symptomatic infections were observed in 8 pwCF (with 2 requiring hospitalization) and in 11 individuals without CF (6 requiring hospitalization). Host transcriptomic analysis revealed that genes involved in protein translation, particularly ribosomal components, were downregulated in CF samples irrespective of SARS-CoV-2 status. In SARS-CoV-2 negative individuals, we found a significant difference in genes involved with motile cilia expression and function, which were upregulated in CF samples. Pathway enrichment analysis indicated that interferon signaling in response to SARS-CoV-2 infection was upregulated in both pwCF and non-CF subjects.
CONCLUSIONS: COVID-19 does not seem to be more severe in CF, possibly due to factors intrinsic to this population: the lower expression of ribosomal genes may downregulate the protein translation machinery, thus creating an unfavorable environment for viral replication.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society - (2024) vom: 19. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ciciriello, Fabiana [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Covid-19 |
|---|
| Anmerkungen: |
Date Revised 20.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.jcf.2024.03.006 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36998529X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36998529X | ||
| 003 | DE-627 | ||
| 005 | 20240322001440.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240322s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jcf.2024.03.006 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1339.xml |
| 035 | |a (DE-627)NLM36998529X | ||
| 035 | |a (NLM)38508950 | ||
| 035 | |a (PII)S1569-1993(24)00036-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ciciriello, Fabiana |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Covid-19 in cystic fibrosis patients compared to the general population |b Severity and virus-host cell interactions |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 20.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2024. Published by Elsevier B.V. | ||
| 520 | |a BACKGROUND: People with cystic fibrosis (pwCF) are considered at risk of developing severe forms of respiratory viral infections. We studied the consequences of COVID-19 and virus-host cell interactions in CF vs. non-CF individuals | ||
| 520 | |a METHODS: We enrolled CF and non-CF individuals, with /without COVID-like symptoms, who underwent nasopharyngeal swab for detection of SARS-CoV-2. Gene expression was evaluated by RNA sequencing on the same nasopharyngeal swabs. Criteria for COVID-19 severity were hospitalization and requirement or increased need of oxygen therapy | ||
| 520 | |a RESULTS: The study included 171 patients (65 pwCF and 106 non-CF individuals). Among them, 10 pwCF (15.4 %) and 43 people without CF (40.6 %) tested positive at RT-PCR. Symptomatic infections were observed in 8 pwCF (with 2 requiring hospitalization) and in 11 individuals without CF (6 requiring hospitalization). Host transcriptomic analysis revealed that genes involved in protein translation, particularly ribosomal components, were downregulated in CF samples irrespective of SARS-CoV-2 status. In SARS-CoV-2 negative individuals, we found a significant difference in genes involved with motile cilia expression and function, which were upregulated in CF samples. Pathway enrichment analysis indicated that interferon signaling in response to SARS-CoV-2 infection was upregulated in both pwCF and non-CF subjects | ||
| 520 | |a CONCLUSIONS: COVID-19 does not seem to be more severe in CF, possibly due to factors intrinsic to this population: the lower expression of ribosomal genes may downregulate the protein translation machinery, thus creating an unfavorable environment for viral replication | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Covid-19 | |
| 650 | 4 | |a Cystic fibrosis | |
| 650 | 4 | |a Gene expression | |
| 650 | 4 | |a RNA sequencing | |
| 650 | 4 | |a Sars-cov-2 | |
| 650 | 4 | |a Virus-host interactions | |
| 700 | 1 | |a Panariello, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Medino, Paola |e verfasserin |4 aut | |
| 700 | 1 | |a Biffi, Arianna |e verfasserin |4 aut | |
| 700 | 1 | |a Alghisi, Federico |e verfasserin |4 aut | |
| 700 | 1 | |a Rosazza, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Annunziata, Patrizia |e verfasserin |4 aut | |
| 700 | 1 | |a Bouchè, Valentina |e verfasserin |4 aut | |
| 700 | 1 | |a Grimaldi, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Guidone, Daniela |e verfasserin |4 aut | |
| 700 | 1 | |a Venturini, Arianna |e verfasserin |4 aut | |
| 700 | 1 | |a Alicandro, Gianfranco |e verfasserin |4 aut | |
| 700 | 1 | |a Oggioni, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Cerino, Pellegrino |e verfasserin |4 aut | |
| 700 | 1 | |a Paiola, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Gramegna, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Fiocchi, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Bandera, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Lucidi, Vincenzina |e verfasserin |4 aut | |
| 700 | 1 | |a Cacchiarelli, Davide |e verfasserin |4 aut | |
| 700 | 1 | |a Galietta, Luis J V |e verfasserin |4 aut | |
| 700 | 1 | |a Colombo, Carla |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society |d 2002 |g (2024) vom: 19. März |w (DE-627)NLM15136754X |x 1873-5010 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:19 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jcf.2024.03.006 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 19 |c 03 | ||